Physician profile
Dawn Chartier
NPI 1285827758
$932.78
in general payments reported to CMS, 2019-2025
11 companies · $89.75 in 2025
The $89.75 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $314 · 2023: $194 · 2024: $63.75 · 2025: $89.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $328.53 | 2021-2023 | Cardiomems |
| Amgen INC. | $137.43 | 2021-2023 | Repatha |
| Lantheus Medical Imaging, INC. | $135.54 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.12 | 2023-2025 | Camzyos, Eliquis |
| Pfizer INC. | $57.38 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $49.15 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $30.60 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $23.09 | 2023 | Optimizer |
| Medicomp INC | $22.21 | 2024 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, LTD. | $20.84 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Chartier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.